RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.2724
https://www.valueinhealthjournal.com/article/S1098-3015(23)05854-0/fulltext
Section Title :
Section Order : 12056
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05854-0&doi=10.1016/j.jval.2023.09.2724
HEOR Topics :
Tags :
Regions :